Chapter 186
Leprosy

Delphine J. Lee, Thomas H. Rea,
& Robert L. Modlin

REFERENCES

1. Skinsnes OK: Immunopathologyz of leprosy: The century in review. *Int J Lepr Other Mycobact Dis* ***41***:329, 1973 [PMID: 4591734]
2. Shepard CC: The experimental disease that follows injection of human leprosy bacilli into foot pads of mice. *J Exp Med* ***112***:445, 1960
3. Ridley DS: Histological classification and the immunological spectrum of leprosy. *Bull World Health Organ* ***51***:451, 1974 [PMID: 4549496]
4. Mitsuda K: On the value of a skin reaction to a suspension of leprous nodules. *Int J Lepr Other Mycobact Dis* ***21***:347, 1953
5. Walsh GP et al: Leprosy-like disease occurring naturally in armadillos. *J Reticuloendothel Soc* ***18***:347, 1975 [PMID: 1214263]
6. Cole ST et al: Massive gene decay in the leprosy bacillus. *Nature* ***409***:1007, 2001 [PMID: 11234002]
7. World Health Organization: Global Leprosy Situation, 2005. *Wkly Epidemiol Rec* ***80***:289-296, 2005
8. World Health Organization: Global leprosy situation, 2007. *Wkly Epidemiol Rec* ***82***:225-232, 2007
9. Newell KW: An epidemiologist's view of leprosy. *Bull World Health Organ* ***34***:827-857, 1966
10. Truman R: Leprosy in wild armadillos. *Lepr Rev* ***76***:198-208, 2005
11. Thomas DA et al: Armadillo exposure among Mexican-born patients with lepromatous leprosy. *J Infect Dis* ***156***:990-992, 1987
12. Mostafa HM et al: Acid-fast bacilli from former leprosy regions in coastal Norway showing PCR positivity for *Mycobacterium leprae*. *Int J Lepr Other Mycobact Dis* ***63***:97-99, 1995
13. Ducan ME et al: A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. *Int J Lepr Other Mycobact Dis* ***51***:7-17, 1983
14. Cho SN et al: Prevalence of IgM antibodies to phenolic glycolipid I among household contacts and controls in Korea and the Philippines. *Lepr Rev* ***63***:12-20, 1992
15. Camacho ID et al: Type 1 leprosy reaction manifesting after discontinuation of adalimumab therapy. *Arch Dermatol* ***145***:349-351, 2009
16. Scollard DM, Joyce MP, Gillis TP: Development of leprosy and type 1 leprosy reactions after treatment with infliximab: A report of 2 cases. *Clin Infect Dis.* ***43***:e19-e22, 2006
17. Cole ST et al: Massive gene decay in the leprosy bacillus. *Nature* ***409***(6823):1007-1011, 2001
18. Krutzik SR et al: TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. *Nat Med* ***11***:653-660, 2005
19. Ng V et al: Role of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobacterium leprae. *Cell* ***103***(3):511-524, 2000
20. Chakravartti MR, Vogel F: A twin study on leprosy. In: *Topics in Human Genetics*, edited by PE Becker. Stuttgart, Georg Thieme, 1973, pp. 1-124
21. Mira MT et al: Susceptibility to leprosy is associated with PARK2 and PACRG. *Nature* ***427***:636-640, 2004
22. de Vries RR, van EW, Ottenhoff TH: HLA class-II immune response genes and products in leprosy. *Prog Allergy* ***36***:95-113, 1985
23. Berrington WR et al: Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. *J Infect Dis* ***201***:1422-1435, 2010
24. Bochud PY, Hawn TR, Aderem A: Cutting edge: A Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. *J Immunol* ***170***:3451-3454, 2003
25. Bochud PY et al: Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. *J Infect Dis* ***197***:253-261, 2008
26. Bochud PY et al: Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy. *Eur J Clin Microbiol Infect Dis* ***28***:1055-1065, 2009
27. Zhang FR et al: Genomewide association study of leprosy. *N Engl J Med* ***361***:2609-2618, 2009

28. Ridley DS: Histological classification and the immunological spectrum of leprosy. *Bull World Health Organ* ***51***:451-465, 1974

29. Ridley DS: *Pathogenesis of Leprosy and Related Diseases*. London, Wright, Butterworth & Co. Ltd., 1988

30. van Brakel WH, Khawas IB: Silent neuropathy in leprosy: An epidemiological description. *Lepr Rev* ***65***:350-360, 1994

31. Khanolkar VR: Pathology of leprosy. In: *Leprosy in Theory and Practice*, 2nd edition, edited by RG Cochrane, TF Davey. Bristol, John Wright and Sons, Ltd, 1964, pp. 125-151

32. Lyde CB: Pregnancy in patients with Hansen's disease. *Arch Dermatol* ***133***(5):623-627, 1997

33. Pedley JC: The presence of *M. leprae* in human milk. *Lepr Rev* ***38***:239-242, 1967

34. Gebre S et al: The effect of HIV status on the clinical picture of leprosy: A prospective study in Ethiopia. *Lepr Rev* ***71***(3):338-343, 2000

35. Trindade MA et al: Leprosy and HIV co-infection in five patients. *Lepr Rev* ***76***:162-166, 2005

36. Scollard DM et al: The continuing challenges of leprosy. *Clin Microbiol Rev* ***19***:338-381, 2006

37. Barnetson RS et al: Cell mediated and humoral immunity in "reversal reactions". *Int J Lepr Other Mycobact Dis* ***44***:267-273, 1976

38. Rea TH, Jerskey RS: Clinical and histologic variations among thirty patients with Lucio's phenomenon and pure and primitive diffuse lepromatosis (Latapi's lepromatosis). *Int J Lepr Other Mycobact Dis* ***73***:169-188, 2005

39. Latapi F, Zamora AC: The "spotted" leprosy of Lucio (la lepra "manchada" de Lucio). *Int J Lepr Other Mycobact Dis* ***16***:421-437, 1948

40. Modlin RL et al: T lymphocyte subsets in the skin lesions of patients with leprosy. *J Am Acad Dermatol* ***8***:182-189, 1983

41. Cooper CL et al: Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by *in situ* hybridization. *J Exp Med* ***169***:1565-1581, 1989

42. Yamamura M et al: Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. *Science* ***254***:277-279, 1991

43. Yamamura M et al: Cytokine patterns of immunologically mediated tissue damage. *J Immunol* ***149***:1470-1475, 1992

44. Krutzik SR et al: Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. *Nat Med* ***9***:525-532, 2003

45. Bleharski JR et al: Use of genetic profiling in leprosy to discriminate clinical forms of the disease. *Science* ***301***:1527-1530, 2003

46. Lee DJ et al: LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. *J Immunol* ***179***:8128-8136, 2007

47. Cruz D et al: Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. *J Clin Invest* ***118***:2917-2928, 2008

48. Bjorvatn B et al: Immune complexes and complement hypercatabolism in patients with leprosy. *Clin Exp Immunol* ***26***:388-396, 1976

49. Rea TH, Shen J-Y, Modlin RL: Epidermal keratonocyte Ia expression, Langerhans cell hyperplasia and lymphocytic infiltration in skin lesions of leprosy. *Clin Exp Immunol* ***65***:253-259, 1986

50. Modlin RL et al: In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. *J Immunol* ***132***:3085-3090, 1984

51. Sampaio EP et al: Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. *J Exp Med* ***175***:1729-1737, 1992

52. Lee DJ et al: Integrated pathways for neutrophil recruitment and inflammation in leprosy. *J Infect Dis* ***201***:558-569, 2010

53. Panunto-Castelo A et al: The Rubino test for leprosy is a beta2-glycoprotein 1-dependent antiphospholipid reaction. *Immunology* ***101***(1):147-153, 2000

54. Worobec SM: Treatment of leprosy/Hansen's disease in the early 21st century. *Dermatol Ther* ***22***:518-537, 2009

55. Jamet P, Ji B: Marchoux chemotherapy study group. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. *Int J Lepr Other Mycobact Dis* ***63***:195-201, 1995

56. Cellona RV et al: Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. *Int J Lepr Other Mycobact Dis* ***71***:308-319, 2003

57. Girdhar BK, Girdhar A, Kumar A: Relapses in multibacillary leprosy patients: Effect of length of therapy. *Lepr Rev* ***71***:144-153, 2000

58. Shetty VP et al: Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. *Lepr Rev* ***76***:241-252, 2005

59. Rea TH: Trials of daily, long-term minocycline and rifampin or clarithromycin and rifampin in the treatment of borderline lepromatous and lepromatous leprosy. *Int J Lepr Other Mycobact Dis* ***68***(2):129-135, 2000

60. Job CK et al: Skin pigmentation from clofazimine therapy in leprosy patients: A reappraisal. *J Am Acad Dermatol* ***23***:236-241, 1990

61. Convit J et al: Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: Preliminary results. *Lancet* ***339***:446-450, 1992

62. Sieling PA et al: CD1-restricted T cell recognition of microbial lipoglycans. *Science* ***269***:227-230, 1995